XML 81 R56.htm IDEA: XBRL DOCUMENT v3.25.4
INDEBTEDNESS - Narrative (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Feb. 03, 2025
USD ($)
Apr. 19, 2024
USD ($)
Jan. 29, 2024
USD ($)
tranche
$ / shares
shares
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jul. 23, 2025
shares
Jul. 21, 2025
$ / shares
shares
Feb. 28, 2025
$ / shares
shares
Nov. 11, 2019
USD ($)
Line of Credit Facility [Line Items]                    
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]     Secured Overnight Financing Rate (SOFR) [Member]              
Warrant to purchase common stock (in shares) | shares     3,076,923       1,408,588 2,115,384 1,153,846  
Exercise price (in dollars per share) | $ / shares     $ 1.30         $ 1.30 $ 1.30  
Warrant exercise period (in years)                 8 years  
Warrant liability       $ 2,980 $ 5,176          
Loss on extinguishment of debt       $ 0 517 $ 0        
Secured Debt | Term Loan Facility | Line of Credit                    
Line of Credit Facility [Line Items]                    
Line of credit, maximum borrowing capacity     $ 55,000              
Line of credit, maximum borrowing capacity, number of available tranches | tranche     3              
Variable rate, floor (as percent)     4.25%              
Basis spread on variable rate (as percent)     6.75%              
Debt instrument, cap rate (as percent)     15.00%              
Debt instrument, interest rate (as percent)       11.00%            
Interest expense       $ 8,400 7,100          
Annual interest rate, increase (as percent)     3.00%              
Late fee percentage     2.00%              
Exit fee percentage     0.75%              
Debt covenant, cash and cash equivalents     $ 15,000              
Debt covenant, revenue period (in months)     12 months              
Debt covenant, revenue     $ 150,000              
Secured Debt | Term Loan Facility | Line of Credit | Minimum                    
Line of Credit Facility [Line Items]                    
Transaction fee percentage     1.00%              
Prepayment fee percentage     1.00%              
Secured Debt | Term Loan Facility | Line of Credit | Maximum                    
Line of Credit Facility [Line Items]                    
Transaction fee percentage     1.25%              
Prepayment fee percentage     4.00%              
Secured Debt | Term Loan Facility, Tranche A | Line of Credit                    
Line of Credit Facility [Line Items]                    
Line of credit, maximum borrowing capacity     $ 37,000              
Proceeds from line of credit     34,500              
Secured Debt | Term Loan Facility, Tranche B | Line of Credit                    
Line of Credit Facility [Line Items]                    
Line of credit, maximum borrowing capacity   $ 8,000                
Proceeds from line of credit   $ 7,500                
Secured Debt | Term Loan Facility, Tranche C | Line of Credit                    
Line of Credit Facility [Line Items]                    
Line of credit, maximum borrowing capacity $ 10,000                  
Proceeds from line of credit $ 9,300                  
Term Loan | Tranche A and B | Keryx | Biopharma Credit Investments V (Master) LP | Collateral Agent, Pharmakon                    
Line of Credit Facility [Line Items]                    
Line of credit, maximum borrowing capacity                   $ 100,000
Interest expense         0 $ 6,000        
Extinguishment of debt     35,000              
Payment of outstanding debt interest and prepayment fee     $ 200              
Loss on extinguishment of debt         $ 500